Libra Infusions Limited Stock

Equities

LIBRAINFU

BD0471LBINF8

Pharmaceuticals

End-of-day quote Dhaka S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
788.6 BDT +2.88% Intraday chart for Libra Infusions Limited +9.48% -14.35%

Financials

Sales 2016 238M 2.17M 2.98M Sales 2017 244M 2.22M 3.06M Capitalization 653M 5.94M 8.18M
Net income 2016 5M 45.47K 62.6K Net income 2017 6M 54.56K 75.11K EV / Sales 2016 6.88 x
Net Debt 2016 880M 8M 11.01M Net Debt 2017 894M 8.13M 11.19M EV / Sales 2017 6.34 x
P/E ratio 2016
131 x
P/E ratio 2017
107 x
Employees 699
Yield 2016
0.41%
Yield 2017
0.57%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Libra Infusions Limited Announces Cash Dividend for the Year Ended June 30, 2021 CI
Libra Infusions Limited Announces Expansion of Large Brand New Dialysis Fluid Production Plant CI
Libra Infusions Limited Recommends Cash Dividend CI
Libra Infusions Limited Reports Earnings Results for the Third Quarter Ended March 31, 2019 CI
Libra Infusions Ltd. Reports Earnings Results for the Second Quarter Ended December 31, 2018 CI
Libra Infusions Limited Announces Unaudited Financial Results for the First Quarter of 2019 CI
Libra Infusions Limited Announces Financial Results for the Year Ended June 30, 2018 CI
Libra Infusions Limited Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 2018 CI
Libra Infusions Limited Reports Unaudited Earnings Results for the First Quarter Ended September 30, 2017 CI
Libra Infusions Limited Recommends Cash Dividend for the Year Ended on June 30, 2017 CI
Libra Infusions Limited Reports Earnings Results for the Year Ended on June 30, 2017 CI
Libra Infusions Limited Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2017 CI
Libra Infusions Limited Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2016 CI
Libra Infusions Ltd. Reports Unaudited Earnings Results for the First Quarter Ended September 30, 2016 CI
Libra Infusions Ltd. Reports Earnings Results for the Year Ended June 30, 2016 CI
More news
1 day+2.88%
1 week+9.48%
Current month+2.99%
1 month+4.74%
3 months-13.07%
6 months-27.57%
Current year-14.35%
More quotes
1 week
682.30
Extreme 682.3
809.90
1 month
682.30
Extreme 682.3
809.90
Current year
682.30
Extreme 682.3
950.00
1 year
445.73
Extreme 445.7333
1 146.67
3 years
350.00
Extreme 350
1 146.67
5 years
292.60
Extreme 292.6
1 146.67
10 years
153.61
Extreme 153.6111
1 146.67
More quotes
Managers TitleAgeSince
Founder - 76-02-01
Director of Finance/CFO - -
Chairman - -
Members of the board TitleAgeSince
Founder - 76-02-01
Chairman - -
Director/Board Member - -
More insiders
Date Price Change Volume
24-04-29 788.6 +2.88% 37 138
24-04-29 766.5 -2.37% 25,098
24-04-28 785.1 +4.12% 42,915
24-04-25 754 +7.19% 26,342
24-04-24 703.4 +0.73% 14,986

End-of-day quote Dhaka S.E., April 29, 2024

More quotes
Libra Infusions Ltd is a Bangladesh-based company engaged in manufacturing of Intravenous (I.V.) fluid. The Company's products include LIBOTT, LIBOTT-10, LIBOTT-25, LIBOTT-S, LIBOTT-S JR, NORMASOL, BABY SALINE, DIASOL, HARTSOL, LIBRAZOL, LIBRACIN, LIBOTT-M, LIBRACIN-400 AND LIBRET. Its products are medical necessities used in medical situations involving diarrheal disease, surgical operation, loss of blood, weakness and hospitalization in general. LIBOTT is used for rehydration at the time of water deficit, general weakness and post-surgical intervention. LIBOTT-10 is used for the treatment of jaundice, general weakness, eclampsia and pre-eclampsia. LIBOTT-25 is used in the emergency treatment of severe hypoglycemia. LIBOTT-S is used for rehydration during general weakness, water deficiency along with sodium, diuresis, intoxication and post-surgical intervention. LIBOTT-S JR fulfills water deficit along with low deficiency of sodium chloride and supplies energy for growing children.
More about the company
  1. Stock Market
  2. Equities
  3. LIBRAINFU Stock